OKE
61
2
KLAC
45
3
EBAY
42
2
GM
55
6
NTAP
58
3
WFC
58
8
APH
53
3
CAG
34
3
AIG
38
5
BLK
46
2
CTSH
55
3
A
43
2
AA
27
5
CHRW
53
2
L
54
5
NEE
39
9
NDAQ
46
2
MDT
59
4
PVH
58
5
PNR
56
2
OKE
61
2
KLAC
45
3
EBAY
42
2
GM
55
6
NTAP
58
3
WFC
58
8
APH
53
3
CAG
34
3
AIG
38
5
BLK
46
2
CTSH
55
3
A
43
2
AA
27
5
CHRW
53
2
L
54
5
NEE
39
9
NDAQ
46
2
MDT
59
4
PVH
58
5
PNR
56
2
Financhill
Back

Keros Therapeutics 10K Form

Sell
4

KROS
Keros Therapeutics

Last Price:
$17.04
Seasonality Move:
16.43%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KROS News And Ratings

See the #1 stock for the next 7 days that we like better than KROS

KROS Financial Statistics

Sales & Book Value

Annual Sales: $151K
Cash Flow: $-30.9M
Price / Cash Flow: 0
Annual Sales: $13.57
Price / Book: 1.29

Profitability

EPS (TTM): -5.21000
Net Income (TTM): $-181.6M
Gross Margin: --
Return on Equity: -44.6%
Return on Assets: -40.96%

Keros Therapeutics Earnings Forecast

Key Keros Therapeutics Financial Ratios

  • The Research & Development expenses have been 89,574.83% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of KROS is -101,319.21% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Keros Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KROS
CUSIP: 492327
Website: kerostx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 19.03
Quick Ratio: 18.36

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KROS Technical Analysis vs Fundamental Analysis

Sell
4
Keros Therapeutics (KROS) is a Sell

Is Keros Therapeutics a Buy or a Sell?